A new meta-analysis of 24 observational studies from researchers at Columbia University Vagelos College of Physicians and Surgeons found that delirium may cause significant long-term cognitive decline.
The findings were published in JAMA Neurology.
Delirium is the most common surgical complication in adults older than 65. It is also observed in patients with critical illnesses, such as sepsis, respiratory failure, and most recently some cases of COVID-19.
“Delirium is associated with a variety of complications, ranging from patient and family stress, increased hospital costs, increased duration of hospital stay, escalation of care, and increased mortality and morbidity including institutionalization,” said Terry Goldberg, PhD a professor of medical psychology (in psychiatry) and anesthesiology at Columbia University Vagelos College of Physicians and Surgeons who led the current study. “In our study, we discovered it had longer term effects as well.”
According to this study, a patient who experiences an episode of delirium were more than twice as likely to show significant long-term cognitive decline than a patient who did not experience delirium.
Researchers from Columbia University Irving Medical Center conducted a systematic review and analysis of 24 observational studies to determine if delirium was associated with increases in cognitive impairment or dementia incidence at least three months after the patient experienced an episode of delirium and found that patients who experienced delirium demonstrated significantly greater cognitive decline than those patients who did not experience such an episode.
The researchers also examined whether delirium unmasks cognitive decline in those individuals who were already compromised and on a downward trajectory or whether delirium may potentially cause cognitive decline. They developed several specific analyses to arbitrate between these hypotheses including examining studies that included only non-cognitively impaired individuals at baseline, examining studies that included only cognitively impaired participants and determining the association of the proportion of delirium-present subjects with cognitive outcome. The researchers found consistent evidence that delirium was causative in decline.
From a public health standpoint, it is important that we develop better strategies for addressing outcomes related to delirium, as it is associated with increases in mortality, long-term cognitive decline and the cost of care. said Dr. Goldberg. “Assuming that delirium occurs in about 20% of those 11.8 million case of individuals older than 65 years who are hospitalized per year, costs attributable to delirium may be between $143 billion and $152 billion owing to longer hospital stays, outpatient visits, nursing home care, and rehabilitation,” said Dr. Goldberg. “And with evidence pointing toward patients with COVID-19 experiencing delirium in ICUs, it is vital that we gain a better understanding of how to help these individuals, as more people than ever are at risk for cognitive decline.”
The paper is titled “Association of Delirium with Long-Term Cognitive Decline: A Meta-Analytic Study”
Additional authors are Chen Chen, MS (Columbia University Irving Medical Center, New York, NY), Yuanjia Wang, PhD (CUIMC), Eunice Jung, BA (CUIMC), Antoinette Swanson, BA (CUIMC), Caleb Ing, MD (CUIMC) , Paul S. Garcia, MD, PhD (CUIMC) , Robert A. Whittington, MD (CUIMC), and Vivek Moitra, MD (CUIMC).
The study is supported by the Departments of Anesthesiology and Biostatistics, Columbia University Irving Medical Center.
Dr. Garcia reports grants from James S. McDonnell Foundation during the conduct of the study. Dr. Whittington reports grants from National Institute of General Medical Sciences during the conduct of the study and personal fees from Anesthesia and Analgesia outside the submitted work. No other disclosures were reported.
The Columbia University Department of Psychiatry is among the top ranked psychiatry departments in the nation and has contributed greatly to the understanding and treatment of brain disorders. Co-located at the New York State Psychiatric Institute on the NewYork-Presbyterian Hospital/Columbia University Irving Medical Center campus in Washington Heights, the department enjoys a rich and productive collaborative relationship with physicians in various disciplines at the Columbia University Vagelos College of Physicians and Surgeons. Columbia Psychiatry is home to distinguished clinicians and researchers noted for their clinical and research advances in the diagnosis and treatment of depression, suicide, schizophrenia, bipolar and anxiety disorders, eating disorders, substance use disorders, and childhood psychiatric disorders.
Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the Vagelos College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cuimc.columbia.edu or columbiadoctors.org.